Company & Capital insights.
Company analysis, IPO landscape, and M&A trends
Biotech Investment Banking: The Complete Guide for 2026
Complete guide to biotech investment banking: top life science IB firms, deal types (M&A, IPO, licensing), valuation methods, and how to choose the right advisor for your transaction.
Biotech Venture Capital 2026: Definitive Investor Guide
$38B deployed in 2025. Top VC firms, investment stages, therapeutic area preferences, geographic trends, and the NewCo/platform creation trend reshaping biotech funding.
BeiGene: From China Biotech to Global Pharma Powerhouse
$3.8B revenue in 2024, BRUKINSA surpassing Imbruvica, and a 50+ asset pipeline. How BeiGene became China's most successful global biotech.
Biotech IPO & Funding Landscape 2026: The Window Reopens
The biotech IPO market surged back to life in late 2025. Track the biggest offerings, venture trends, and what makes a successful biotech IPO.
Biotech M&A 2026: Navigating the $200B Patent Cliff
A technical analysis of valuation multiples and integration savings in the consolidation wave.
The Vision Lifesciences brief.
One email per month. New essays and deal-flow notes from the partner team. Unsubscribe anytime.